Please try another search
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Name | Age | Since | Title |
---|---|---|---|
Philip Wagenheim | 53 | 2017 | Director |
George C. Prendergast | - | - | Member of Scientific Advisory Board |
Shmuel Shoham | - | 2020 | Member of COVID-19 Advisory Board |
James Patrick Boylan | 56 | 2023 | Director |
Jean-Jacques Bienaime | 71 | 2023 | Director |
Louis M. Weiner | 72 | - | Member of Scientific Advisory Board |
John M. Lambert | 73 | 2023 | Member of Antibody-Drug Conjugate & T Cell Redirection Advisory Board |
Isaac Barchas | 57 | 2023 | Lead Independent Director |
Jeffrey Henderson | - | 2020 | Member of COVID-19 Advisory Board |
Susan Weiss | - | 2020 | Member of COVID-19 Advisory Board |
Andrew D. Badley | - | 2021 | Member of COVID-19 Advisory Board |
William Strohl | 71 | - | Member of Scientific Advisory Board |
Anthony W. Tolcher | - | - | Member of Scientific Advisory Board and Member of ADC & T Cell Redirection Advisory Board |
Clay B. Siegall | 63 | 2023 | President, CEO & Chairman |
Carol A. Schafer | 60 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review